Submit Manuscript  

Article Details


Facile Synthesis and Cytotoxicity of Phenazine-Chromene Hybrid Molecules Derived from Phenazine Natural Product

[ Vol. 22 , Issue. 1 ]

Author(s):

Mei-Chen Zhang, Shu-Hui Gu, Guang-Pan Liu, Chen-Cheng Li, Han-Mei Xu*, Zhong-Xi Wu, Bo-Ping Ye, Yuan-Yuan Lu, De-Chun Huang, Zhi-Xiang Wang and Feng Jiang*   Pages 35 - 40 ( 6 )

Abstract:


Aim and Objective: Small molecule targeted drugs can effectively reduce the toxicity and side effects of drugs, and improve the efficacy of drugs by their specific antitumor activity. Hence, the development of small molecular targeted drugs for cancer has important significance. This study was undertaken to design and synthesize novel phenazine-chromene hybrid molecules in order to optimize the structure and improve the efficacy of this kind of hybrids.

Materials and Methods: O-diaminobenzene was used as starting material to synthesize twentyfour heterocyclic compounds designed as hybrid molecules of phenazine and 4H-chromene pharmacophores by facile methods. The structures of the compound were confirmed by 1H NMR, 13C NMR and HRMS. Furthermore, the synthesized compounds were evaluated for in vitro activity against four human cancer cell lines and two non-cancer cell lines by MTT test.

Results: Some compounds showed strong cytotoxic activities against HepG2 and A549 cancer lines (IC50 = 5-10 µM). Comparing 2i with 2l, the introduction of hydrophilic groups on the phenazine core could not improve the antiproliferative activity significantly. Except 2d and 3c, compounds owning chlorine substituent on the 4H-chromene pharmacophore seemingly contribute to enhance the compounds’ antiproliferative activity. Specially, compound 3c showed highest cytotoxicity against A549 cells with IC50 values of 3.3±0.4 µM. Furthermore, all compounds showed low or no cytotoxicity against HUVEC and L02 non-cancer cells in vitro.

Conclusion: Compound 3c may be used as potential lead molecule against A549 cancer cells.

Keywords:

Phenazine, 4H-chromene, hybrid molecules, antitumor activity, SAR, synthesis.

Affiliation:

School of Engineering, China Pharmaceutical University, Nanjing 210009, School of Engineering, China Pharmaceutical University, Nanjing 210009, The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 210009, The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 210009, The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 210009, School of Engineering, China Pharmaceutical University, Nanjing 210009, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, School of Engineering, China Pharmaceutical University, Nanjing 210009, School of Engineering, China Pharmaceutical University, Nanjing 210009, School of Engineering, China Pharmaceutical University, Nanjing 210009



Read Full-Text article